35 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Synthesis, characterization and antitubercular activities of novel pyrrolyl hydrazones and their Cu-complexes.
S.E.T'S College of Pharmacy
Piperazine derivatives: synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase and SAR studies.
Pontif£Cia Universidade Cat£Lica Do Rio Grande Do Sul
Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
Birla Institute of Technology
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
Astrazeneca
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
Astrazeneca
Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
Birla Institute of Technology
Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.
Glaxosmithkline
Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
Astrazeneca India
Identification of novel antimycobacterial chemical agents through the in silico multi-conformational structure-based drug screening of a large-scale chemical library.
Kyushu Institute of Technology
Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents.
Cnrs
Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Stony Brook University
2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.
University of London
Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.
China Pharmaceutical University
Natural products, small molecules, and genetics in tuberculosis drug development.
National Institute of Diabetes and Digestive and Kidney Diseases
Agonodepsides a and B: two new depsides from a filamentous fungus F7524.
Institute of Molecular and Cell Biology
Synthesis of 4-phenoxybenzamide adenine dinucleotide as NAD analogue with inhibitory activity against enoyl-ACP reductase (InhA) of Mycobacterium tuberculosis.
University of Minnesota
An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.
University of Kwazulu-Natal (Westville)
Boron-Containing heterocycles as promising pharmacological agents.
Long Island University
Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Erciyes University
Exploring the chemical space of 1,2,3-triazolyl triclosan analogs for discovery of new antileishmanial chemotherapeutic agents.
Instituto De Qu£Mica Rosario
Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
Nanjing University
Discovery of novel N-methyl carbazole tethered rhodanine derivatives as direct inhibitors of Mycobacterium tuberculosis InhA.
University of Kwazulu-Natal (Ukzn)
Synthesis and Structure-Activity Relationship Studies of C2-Modified Analogs of the Antimycobacterial Natural Product Pyridomycin.
Eth Zurich
Synthesis and antimycobacterial activity of 2,1'-dihydropyridomycins.
Swiss Federal Institute of Technology (Eth) Zurich
An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors.
Cnrs
Recent advances of pyrazole-containing derivatives as anti-tubercular agents.
Wuhan University of Science and Technology
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
West China Hospital
